GLP-1 vs older weight-loss pills: an honest comparison
GLP-1 receptor agonists like semaglutide and tirzepatide produce much larger weight loss, about 10 to 21 percent in trials, than the older pills, which mostly sit around 5 to 10 percent. But the GLP-1 drugs are injectable (apart from oral semaglutide for diabetes), far more expensive, and carry their own gut, muscle and gallbladder risks. The older pills are oral, cheaper and longer-studied, but their effect is modest and each has its own trade-off, from stimulant heart risks to birth defects. No medicine is a free lunch; the right choice depends on your BMI, your conditions, your budget, your side-effect tolerance and what is actually available in India, decided with your doctor.
If you are looking at weight-loss medicines, two big families come up. The new one is the GLP-1 receptor agonists, the injectables like semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Saxenda). The older one is the pills, like orlistat, phentermine, phentermine/topiramate (Qsymia) and naltrexone/bupropion (Contrave). People hear the big GLP-1 numbers and assume the new drugs are simply better and the old pills are now useless. This guide gives you the honest head-to-head, because the choice is not that simple. The GLP-1 drugs produce far more weight loss in trials, but they are injectable (except oral semaglutide, sold as Rybelsus for diabetes), they are very expensive, and they have their own gut, muscle and gallbladder risks. The older pills are oral, cheaper and have been used for many years, but their effect is modest, and each carries its own real risks, from heart and dependence issues to birth defects and seizures. In India, what you can actually get shapes the choice heavily: orlistat is widely available, liraglutide has some options, semaglutide and tirzepatide are costly branded imports, phentermine is restricted, and Qsymia and Contrave are not standard here. Please talk to your doctor before any medicine decision.
The baseline: no medicine is a free lunch
Here is the honest principle to hold before any comparison. A bigger weight-loss effect usually comes with a bigger cost, a harder way of taking it, or a different kind of risk. There is no medicine that gives you large weight loss for free. The US National Institute of Diabetes and Digestive and Kidney Diseases says that after one year, adults on prescription weight-loss medicines as part of a lifestyle program lose about 3 to 12 percent more of their starting body weight than people on lifestyle alone, and that some people lose 10 percent or more. So even at the high end, these are tools that work with diet and movement, not instead of them. The same institute says doctors usually suggest stopping if you have not lost at least 5 percent of your starting weight after 12 weeks on the full dose. That rule quietly tells you two things: the effect varies a lot between people, and a medicine that does not work for you is just a risk with no benefit. The GLP-1 drugs sit at the top of the range for effect (semaglutide 2.4 mg gave about 14.9 percent loss and tirzepatide up to about 20.9 percent in trials), while the older pills sit lower (around 5 to 10 percent). But the bigger number also comes as a weekly injection, at high cost, with nausea and gut effects, and with muscle and gallbladder concerns. The smaller-number pills are oral and cheaper, but modest, and each carries its own warning. The choice is always a trade-off, and it belongs with your doctor.
The strongest weight-loss medicine is always the best choice.
falseFalse. The biggest weight-loss number does not automatically mean the best medicine for you. The GLP-1 drugs do produce the largest losses in trials (semaglutide about 14.9% and tirzepatide up to about 20.9%), but they also come as a weekly injection, cost a lot, can cause nausea and gut effects, and raise gallbladder and muscle concerns. The older pills give less, around 5 to 10%, but some are oral, cheaper and have been used for decades. Each older pill also carries a real, specific risk: phentermine is a stimulant that can raise heart rate and blood pressure; Qsymia can cause birth defects (cleft lip and/or palate) and is contraindicated in pregnancy; Contrave (bupropion) can cause seizures and carries a suicidal-thoughts warning; orlistat causes oily gut side effects and cuts absorption of fat-soluble vitamins. NIDDK notes that even the eligibility for these medicines depends on the person, a BMI of 30 or greater, or 27 or greater with weight-related conditions like high blood pressure or type 2 diabetes, and that if you do not lose at least 5% of starting weight after 12 weeks on the full dose, your doctor will likely advise stopping. So the right choice depends on your BMI, your health conditions, your budget, your side-effect tolerance, and what is actually available where you live. The strongest medicine is not always the best; the best one is the one that fits you and is supervised by your doctor.
How to think about the choice with your doctor
- Start with your BMI and conditions, not the headlines. NIDDK says these medicines are for adults with a BMI of 30 or greater, or 27 or greater with weight-related problems like high blood pressure or type 2 diabetes. Let your doctor confirm you actually fit the criteria before any medicine.
- Be honest about your budget. GLP-1 pens can cost many thousands of rupees a month in India and are ongoing; orlistat is far cheaper. A medicine you cannot keep paying for is not a sustainable plan.
- Weigh the side-effect tolerance you can live with. If oily gut side effects would make you quit, orlistat is a poor fit. If injections and nausea are a hard no, GLP-1 may not suit you. Tell your doctor what you can and cannot tolerate.
- Check what is actually available in India. Orlistat is widely sold as generics; liraglutide has some options; semaglutide and tirzepatide are costly branded imports; phentermine is restricted and Qsymia and Contrave are not standard here. Local access narrows the real list a lot.
- Ask about the stop rule. NIDDK says if you have not lost at least 5% of starting weight after 12 weeks on the full dose, your doctor will likely advise stopping. Agree on this checkpoint upfront so you do not keep paying for and risking a medicine that is not working for you.
- Never self-medicate or buy online without a prescription, especially the injectables. Wrong dosing, fakes and broken cold storage can make a helpful medicine harmful.
- Keep the lifestyle base. All of these are meant to work with a reduced-calorie diet and movement, not instead of them. Burnie can help you log your food and see your daily calorie deficit alongside whatever your doctor prescribes.
The bottom line
There is no free lunch in weight-loss medicines. The GLP-1 drugs (semaglutide, tirzepatide, liraglutide) give the biggest losses in trials, up to about 21 percent, but they are injectable, expensive, and carry gut, muscle and gallbladder risks. The older pills (orlistat, phentermine, Qsymia, Contrave) give less, around 5 to 10 percent, but each has its own real trade-off: stimulant heart and dependence risk, birth defects, seizures, or oily gut side effects and vitamin loss. In India the real list is narrowed further by cost and access. The honest bottom line is that the best medicine is not the strongest one, it is the one that fits your BMI, your conditions, your budget, your side-effect tolerance and your local access, chosen with your doctor and paired with a calorie-conscious lifestyle. Burnie can help you log your food and watch your daily calorie deficit, but every medicine decision belongs with your doctor, not an ad or an online deal.